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Background: Oral anticoagulant therapy is used to prevent thrombosis in patients with atrial fibrillation (AF),
venous thrombosis and prosthetic heart valves. The introduction of new therapies emphasizes the need to discern
the best practice for the patients remaining on warfarin treatment. This study compares patient characteristics and
therapeutic control in two settings managing warfarin treatment: Swedish primary health care centers (PHCC) and
specialized anticoagulation clinics (ACC).
Methods: Prothrombin time (PT) test results reported as International Normalized Ratio (INR) were collected for five
consecutive days from patients on warfarin treatment; 564 PHCC and 927 ACC patients. Therapeutic control was
calculated as PT test results in relation to intended therapeutic range (TR). Mann–Whitney Rank Sum Test and Chi2 test
were used for statistical comparisons.
Results: The PHCC patients were older than the ACC patients, 76 v. 70 years (p<0.01) with a predominance of men in
both groups. The reasons for treating differed between the groups. Seventy-two percent of PHCC patients and 66% of
ACC patients had a PT-INR within the intended TR (p<0.05). Men generally had better results than women (72% v. 63%,
p<0.001) and particularly in the PHCC group v. the ACC group (78% v. 69%, p<0.01).
PT-INR above intended TR was significantly more common in the ACC setting, (p<0.05), for women overall (p<0.01), for
women in the PHCC setting, and for ACC men (p<0.05).
Conclusions: In this study both settings achieved good therapeutic control of warfarin treatment with a minor
advantage for PHCC over ACC, and better results for men, especially in the PHCC setting. As patient characteristics
differ between the PHCC and ACC, it is important to conduct further randomized studies to discern the best practice
locally for warfarin management also after the introduction of new drugs.
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Oral anticoagulant therapy (OAT) is used to prevent
thrombosis in patients with atrial fibrillation (AF), venous
thrombosis and prosthetic heart valves. The numbers of pa-
tients on OAT is steadily increasing worldwide. Although
new drugs are being introduced, vitamin K antagonists* Correspondence: kerstin.arbring@lio.se
1Department of Medical and Health Sciences, Linköping University,
Department of Acute Internal Medicine, County Council of Östergötland,
S581 85, Linköping, Sweden
Full list of author information is available at the end of the article
© 2013 Arbring et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(VKA) still predominate. The introduction of new therapies
emphasizes the need to discern the best practice for pa-
tients remaining on warfarin treatment. In Sweden, the
number of VKA-treated patients is approaching 200,000,
almost 2% of the population, and the treatment is almost
exclusively warfarin.
Good therapeutic control of VKA treatment, with
regular prothrombin time (PT) tests reported as Inter-
national Normalized Ratio (INR) within intended thera-
peutic range (TR) is imperative for minimizing adverse
events (bleeding and/or thrombosis) [1-4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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control in community-based patients with AF in the USA
was similar to participants in clinical trials [5]. Prospective
data on VKA management are limited, but most retro-
spective studies favor specialized anticoagulation clinics
(ACCs) over “usual care” [1,4,6]. However, these results
cannot be automatically extrapolated to Sweden, which
has a high standard of VKA management and primary
health care. This is exemplified by the recent Swedish na-
tional quality registry—Auricula—study, which showed
that the quality of anticoagulation treatment in Swedish
centers is high, with a mean TTR of 76.2% [7].
A previous Swedish study found no differences in
bleeding complications between Swedish primary health
care centers (PHCC) and ACC [8].
Although the general trend in Sweden is toward more
centralized (ACC) management of VKA treatment, some
counties prefer to use the patient’s PHCC instead. There
is, theoretically, a third option, with patients testing
themselves with or without self-management of dosing.
However, this group is very small in Sweden, estimated
at fewer than 1,000 patients.
Most study data about the therapeutic control of VKA
treatment originates from centralized ACCs with com-
puter registers for treatment data, leaving the more
scattered and hard-to-access PHCC data relatively unex-
plored. At the time this study was conducted, both re-
gimes, ACC and PHCC VKA management, coexisted in
our region. Both settings offered similar services, includ-
ing initiation/induction and continued treatment.
Delivery of care for patients requiring warfarin therapy
can be organized according to completely different prin-
ciples. The different settings should therefore be charac-
terized and compared, preferably with actual “real-life”
populations not subjected to interventional studies
where the patient material is usually selected, before de-
ciding which organization is best suited to satisfy local
health care challenges. The introduction of new therap-
ies, with an obvious impact on future management of
anticoagulation therapy, further emphasizes the need to
conduct studies to determine best practice for warfarin
management.
The Rosendaal method [9], commonly used for Time
in Therapeutic Range (TTR) calculations, is very cum-
bersome to perform in non-computerized settings. A
cross-sectional method is more feasible in such a setting
and was therefore chosen for this particular study.
The purpose of the present observational study was to
perform a non-selective, snapshot cross-section com-
parison of the main patient characteristics and thera-
peutic control in the two different settings (PHCC and
ACC) used for managing VKA treatment in a large
population in our region. This also includes an investiga-
tion of potential differences between these two settingswith respect to the proportion of PT-INR results within
TR overall, and between men and women.
Methods
We performed a cross-sectional study of an unselected
material of patients on warfarin treatment managed by
Swedish PHCCs and ACCs.
The study period was February 23 to February 27,
2004 (Monday to Friday, the days of the week when the
ACCs and PHCCs are open). The raw material consisted
of PT results from this week.
The treatment was monitored by regular analysis of
PT using one combined thromboplastin from Medirox
(Studsvik, Sweden). Instruments used were ACL 10 000
and ACL Futura from IL (Milan, Italy), Start from
Diagnostica Stago (Asnières sur Seine, France) and
Behnk Coagulator from Behnk Electronics (Norderstedt,
Germany). Capillary blood samples were analyzed at the
local laboratory or at the anticoagulation clinics; the
quality was controlled by running control samples daily
and by comparing split samples with the central labora-
tories at Linköping University Hospital or Jönköping
Hospital.
All PT test results (reported as INR) from the central
health care district of Östergötland County for the study
period were collected from the laboratory information
system (Flexlab™, TietoEnator, Linköping, Sweden); a
total of 563 PHCC PT-INR test results. In case of mul-
tiple tests per patient, the first one was registered and
subsequent test(s) were then removed. Forty-six dupli-
cate tests were thus removed. The 16 PHCC centers in
Östergötland each tested between 10 and 53 unique pa-
tients during the study period.
Information about the patients regarding intended TR
and the reason for warfarin treatment was manually col-
lected retrospectively from each PHCC. Eighteen test re-
sults from patients not on warfarin treatment, or where
neither information regarding intended TR nor cause for
treatment could be obtained, were further excluded.
All PT tests registered for the same period in the data-
base of the ACC of Linköping University hospital and
the ACC in Värnamo were collected (n=551 and 425, re-
spectively) and duplicates were excluded as described
above (n=81 and 26, respectively).
In addition, all PT tests for the same period and for
warfarin-treated patients in the Eksjö area (one PHCC
and one ACC) were reported to us. Duplicate tests were
removed in Eksjö before the results were sent to us; only
the PT-INR test results of unique patients (n=65 and 58
for the PHCC and ACC, respectively) were reported to
us, along with anonymous patient data.
The reported cause for treatment for all patients was
classified as venous thromboembolism (VTE, deep
vein thrombosis and/or pulmonary embolism), atrial
Table 2 Causes for warfarin treatment for each setting
VTE AF Valve Other Total
PHCC 162 (29%) 281 (50%) 17 (3%) 100 (18%) 560
ACC 222 (24%) 383 (42%) 157 (17%) 153 (17%) 915
VTE=Venous thromboembolism, AF=Atrial fibrillation, Valve=Heart valve
disease, Other=Other or multiple cause for treatment.
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ease (Valve, including/primarily mechanical valve pros-
thesis) or other cause (Other, e.g. peripheral arterial
embolism, other cardiac disease, stroke without any in-
formation on concomitant atrial fibrillation, or multiple
causes).
All three ACCs and the PHCC in Eksjö recorded their
patient data (including cause for treatment and intended
TR) in a computer register, but the dosing was done
manually in all centers. The remaining PHCCs used
paper registers. No specific dosing algorithm was sys-
tematically used.
Statistics were calculated by Sigmaplot for WindowsW
11.0 (Systat Software Inc.W) and Microsoft Office ExcelW
2003 and 2007.
The study was approved by the Regional Ethical Re-
view Board in Linköping.
Results
The total number of PT-INR tests originating from
unique patients (after exclusion as described in the
Methods section) and the number of patients with
known and reported TR and cause for treatment are
shown in Table 1.
The PHCC patients were older than the ACC patients,
average age 76 and 70 years, median 78 and 74 years, re-
spectively (p <0.001, Mann–Whitney Rank Sum Test).
There were significantly more men in the PHCC group
than in the ACC group, 51% and 58% respectively,
(Chi2-test, p<0.01).
Reported causes for warfarin treatment for the PHCC
and ACC groups are presented in Table 2. The causes
differed between PHCC and ACC groups, with more
heart valve disease patients in the ACC group.
The intended range was 2 (or 2.1) – 3 (or 3.1) for 93%
(509/545) and 89% (826/927) in the PHCC and ACC
groups, respectively, 2.5-3.5 for 1% (5/545) and 4% (41/
927). Two and 11 patients were reported to have inter-
vals with a width greater than 1.4 in the PHCC andTable 1 Number of PT-INR tests (unique patients), known/
reported therapeutic range and cause for treatment
Location PT-INR tests Range stated Cause stated
PHCC Östergötland 499 480 495
PHCC Eksjö 65 65 65
PHCC total
(men/women)
564 (289/275) 545 (282/263) 560 (289/271)
ACC Östergötland 470 470 464
ACC Eksjö 58 58 58
ACC Värnamo 399 399 393
ACC Total
(men/women)
927 (540/387) 927 (540/387) 915 (531/384)
ACC = Anticoagulation clinics, PHCC = Primary health care centers.ACC groups, respectively, and 19 and 23 patients were
reported to have intervals with a width of 0.5 or less in
the respective groups.
When relating the PT-INR values to the intended TR,
72% of the PHCC patients and 66% ACC patients were
within their TR, a small but statistically significant dif-
ference (Chi2-test, p<0.05), see Figure 1.
For the male patients 72% of the PT-INR values were
within the intended TR, a significantly higher proportion
compared with 63% for the female patients (Chi2-test,
p<0,001). There was no significant difference between the
PHCC and ACC groups of female patients, whereas the
tests from the male patients were within intended TR at a
significantly higher proportion in the PHCC group than in
the ACC group: 78% in the PHCC group and 69% in the
ACC group (Chi2-test, p<0.01). The distribution of crude
PT-INR test results for these groups is shown in Figure 2,
and the distribution of PT-INR test results related to the
intended TR for the patient is shown in Table 3.
The number of PT-INR tests results above the
intended TR was significantly higher in the ACC setting
(15%) than in the PHCC setting (11%), (Chi2-test,
p<0.05) and in women than in men overall (16% v. 11%,
Chi2-test, p<0.01). No significant difference was found
between settings for women, but for men the proportion
of PT-INR test results above the intended range was
significantly higher in the ACC setting than the PHCC
setting (13% v. 7%, Chi2-test, p<0.05). In the ACC
setting, there were no significant gender-related differ-
ences in test results. However, in the PHCC setting,
the number of PT-INR tests above intended TR was
significantly higher in women than in men (15% v. 7%,
Chi2-test, p<0.01).
No significant difference was found related to PT-INR
test results below intended TR either between the set-
tings, between male and female patients overall, or in
each respective setting.
The number of objectively high PT-INR results (PT-
INR>5) was 1 and 5 (both less than 1%) for the respective
PHCC and ACC groups, which was non-significant. Also
no significant difference was found in the number of ob-
jectively low PT-INR results (PT-INR<1.8), 41 (8%) and 79
(9%) for the PHCC and ACC groups, respectively.
Discussion
The latest American College of Chest Physicians (ACCP)


















Within/outside intended Therapeutic Range (TR)
Outside TR
Within TR
Figure 1 PT-INR test results within and outside intended therapeutic range. PHCC = Primary health care centers (PHCC) and
ACC = Anticoagulation clinics (ACC settings).
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ies and a few retrospective, comparative studies have
reported better outcomes for the ACC setting compared
with what is called “usual care” by personal physicians.
They also found that four prospective, randomized con-
trolled studies failed to show a significant difference in
major hemorrhage or thromboembolism. The conclud-
ing ACCP Best Practices Statement [4] maintains that
“health-care providers who manage oral anticoagulation
therapy should do so in a systematic and coordinated
fashion, incorporating patient education, systematic INR
testing, tracking, follow-up, and good patient communi-
cation of results and dosing decisions” giving guidance












Figure 2 PT-INR test results for men and women in ACC and PHCC.In this study of Swedish settings, we found a small ad-
vantage for the PHCC over the ACC and better results
for men, especially in the PHCC setting. The reported
characteristics in this study are different for the PHCC
and ACC patients. We are aware that, since additional
patient characteristics might differ between PHCC and
ACC patients, lack of multivariate models that further
explore associations between these potential differences
and INR control is an obvious limitation in our study.
Our aim was to study “real-life” VKA treatment patients
as managed on a routine basis and unfortunately, add-
itional patient characteristics (e.g. co-morbidities) were
not registered systematically, neither at the ACC nor at
the PHCC (and this is still the practice).MEN-PHCC WOMEN-PHCC
Table 3 Distribution of PT-INR test results for each
setting
Location Below range Within range Above range
PHCC (men/women) 93 (42/51) 392 (219/173) 60 (21/39)
ACC (men/women) 181 (100/81) 609 (370/239) 137 (70/67)
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directing of more complicated patients to the ACC in
our region. However, as our study was not randomized,
we cannot exclude a referral bias. The older age of the
PHCC patients may indicate a population with more
concomitant disease, but we cannot exclude the possibil-
ity that the ACC patients may be medically equally com-
plicated. The difference in characteristics may be of
importance in itself; Poli [10] recently found better
therapeutic control in AF than in VTE patients in an ob-
servational study on elderly patients.
Although both settings handle patients during the war-
farin induction phase, with its potential out-of-range
PT-INR values, we cannot exclude a slight overrepresen-
tation of patients in the induction phase in the ACC
compared with the PHCC. It can also be speculated that
ACC patients might more often be subjected to different
procedures that require a warfarin withdrawal followed
by a “re-induction phase”. These temporary out-of-range
PT tests would have less impact in a TIR interpolation
model such as Rosendaal’s [9,11].
A high-standard PHCC setting offers many advantages
as primary health care physicians may have a better op-
portunity to keep track of concomitant medication and
other medical, practical and social circumstances that
could have an impact on the warfarin treatment.
Male patients seem to do better, especially in the
PHCC setting. We have no definite explanation for this.
Small food portions with a higher risk of low vitamin K
intake in women might contribute, but that does not ex-
plain a better outcome for men in the PHCC setting.
The data in this study was accumulated in 2004 and we
cannot be sure if the results of our study are equally ap-
plicable to practice today. However, our study makes an
objective comparison of two different settings at a time –
point when both settings were equally experienced in
managing warfarin treatment. Such a fair appraisal of both
settings will help health-care professionals to choose the
optimal local setting for future management of warfarin
treated patients, alongside with the patients treated with
the new oral anticoagulants.
Conclusions
We conclude in the present study that both Swedish
settings achieved good therapeutic control. Objective
comparison of data from different settings, optimally
head-to-head in a randomized, prospective study thateliminates differences in patient characteristics, is important
before deciding which organization is best suited to satisfy
local health care needs. This study and further studies com-
paring the different settings will assist health care profes-
sionals in choosing the optimal setting for future delivery of
care for warfarin patients, based on local conditions.
The coming expected diversity of oral anticoagulants
will present new organizational challenges for the delivery
of adequate care for all patients requiring anticoagulation
therapy. As of today, just above 2,000 patients in Sweden
are being treated with dabigatran, the first new oral anti-
coagulant on the Swedish market. More drugs are being
introduced. The advent of these new therapies will also
pose difficult questions regarding optimal management of
warfarin therapy for patients remaining on warfarin.
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